Genetic predisposition, susceptibility to environmental stimuli and autoimmune mechanisms interact to cause Type 1 (insulin-dependent) diabetes mellitus. The appearance of Type i diabetes is accompanied by multiple circulating autoantibodies: islet cell antibodies (ICA), islet cell surface antibodies (ICSA), insulin autoantibodies (IAA) and anti-64 kilodalton (kd) antibodies. Some of these autoantibodies are observed in 50-90% of newly diagnosed Type i diabetes patients and in 30-50% of their first degree relatives [1] [2] [3] [4] [5] . There is accumulating evidence which supports the importance of T-cell mediated autoimmunity in the initiating events of the islet Beta-cell destruction [6] [7] [8] .
We have recently reported that one of the changes which occur in human T lymphocytes during activation with conconavalin A is the appearance of a peptide of 43 kd coded by a unique mRNA species [9] . This peptide cross-reacted with a CM-H-9 monoclonal antibody which is specific for placentalisoferritin (PLF) [10] . PLF is an immunosuppressive protein [11] , acting as a down regulator of the immune response of mothers against their embryos [12] . High levels of PLF were measured with CM-H-9 monoclonal antibody in women during pregnancy whereas it is below detection in the majority of healthy adult blood donors [13] . Elevated levels of PLF were also measured in serum, from patients with pathological conditions such as lymphoproliferative disorders, and breast cancer [14, 15] , in patients with autoimmune diseases such as coeliac disease [16] and multiple sclerosis (unpublished observations) in which T cell involvement has been reported in the aetiology of the disease, and in patients with HIV infection [17] .
The above findings prompted us to investigate whether Type i diabetes is also associated with high serum levels of PLE
Subjects and methods

Subjects
Included in the study were three groups of Type i diabetic patients, all treated in the Institute of Pediatric and Adolescent Endocrinology, Beilinson Hospital. The first group consisted of 50 patients (29 male, 21 female) age 2.5-29 years (12.5 _+ 4.8 years, mean + SD) with Type i diabetes, new-onset or insulin-treated for 1-7 days. The second group consisted of 23 patients (13 male, 10 female) age 3.5-20 years (13.3 _+ 4.1 years) under insulin treatment for a period of 2-28 weeks and the third group, 7 patients treated with insulin for a period of one year.
In addition, 100 healthy first-degree relatives were included: 27 mothers, 27 fathers, 46 siblings ( Blood samples from Type 1 diabetic patients are routinely obtained in our Institue for standard diagnostic laboratory tests. Blood samples from the family members were collected for the screening of high risk relatives of the diabetic proband. The healthy subjects had been referred to the Institute for developmental evaluation and blood was drawn for routine examinations. Informed consent was obtained from all patients, control subjects and from their parents. The study was approved by the Israel Ethical Comittee and the Ministry of Health.
Laboratory methods
Assay for ICA. ICA were determined by an indirect immunofluoresence technique on unfixed cryostat sections of blood group 0 pancreas [1] .
Assay for PLE Serum PLF levels were determined by a previously described ELISA method [14] . The assay utilised two monoclonal antibodies (CM-G-8 and CM-H-9). CM-G-8 monoclonal antibody binds to all isoferritins whereas CM-H-9 monoclonal antibody binds to PLF only [10] . The amount of PLF that bound 250 pg of alkaline-phosphatase conjugated CM-H-9 monoclonal antibody was arbitrarily considered to be 10/U of PLF and the results were expressed as U/ml.
Statistical analysis
Values are given as median and range. Because PLF values showed skewed distribution the Mann-Whitney U-test (two-tailed probability) was used. Correlation between the age and PLF values was calculated by regression analysis.
Results
A scattergram of the serum levels of PLF in the Type 1 diabetic patients, their first degree-healthy family members, normal control subjects and the Type 2 diabetic patients is presented in Figure 1 . A wide range of serum PLF levels was observed in the diabetic patients as well as in some of their healthy family members. In contrast, PLF was undetected or at very low levels in most subjects of the control group and in the Type 2 diabetic patients. ICA were found in 31 of 44 diabetic patients tested of whom 17 (54.8%) had elevated PLF levels, above 10 U/ml (not shown). ICA were positive in 8 of 71 tested healthy family members of Type i diabetic patients of whom 4 (50%) also had elevated serum PLF levels (not shown). All the control subjects were ICA negative. The median and range serum PLF level (24, 0-140 U/ml) in the Type i diabetic patients was significantly higher (p < 0.0001) than in their family members (0, 0-73 U/ml) and in that of normal control subjects (0,0-29 U/ml;p < 0.0001) ( Table 1) .
Designating 0-10 U/ml as a normal level of PLF, it was found that 62% of Type i diabetic patients had an elevated PLF level compared to 25% of their family members, 8.6% of the control subjects and 2.9% of Type 2 (non-insulin-dependent) diabetic patients (Table 1) . Period of insulin treatment (months) Fig. 3 . Serum placental isoferritin (PLF) levels in Type 1 (insulin-de-
pendent) diabetic patients during one year of insulin treatment
No statistically significant correlation was found between the age and PLF values in the patients with Type 1 diabetes (r = -0.189) or in the control subjects (r = -0.125).
Among the family members, the highest percentage of elevated PLF results were found in the siblings of the Type i diabetic patients (30.4%). In mothers and fathers, positive results were found in 22.2% and 18.5%, respectively of those tested parents (Table 2) . It was further observed that in relatives of Type i diabetic patients with positive PLF results, 37.8% were PLF positive as com-559 pared to 0% in relatives of PLF negative probands (Table 3) . Further, the level of serum PLF was measured in Type 1 diabetic patients under insulin treatment. As seen in Figure 2 , decreased mean PLF levels were observed in patients under insulin treatment. The lowest level was measured in the group treated with insulin for 2-28 weeks. It was significantly lower (p < 0.002) than in Type i diabetic patients as diagnosis and was similar to the level of the control group. The early decrease of serum PLF levels in Type 1 diabetic patients following insulin treatment, was further confirmed in seven patients tested repeatedly during one year. It can be seen in Figure 3 , that a sharp decline was observed in 6 of 7 patients tested, after one month of insulin treatment. This effect was stable for one year of follow-up (Fig. 4) .
Discussion
The results of the current study revealed that PLF was significantly elevated in patients with Type 1 diabetes at diagnosis and in some of their family members, but not in Type 2 diabetes.
To date, the tests for diagnosis of autoimmune Type 1 diabetes and family members at risk, included determination of humoral autoantibodies i. e. ICA, ICSA, IAA and anti-64KD antibodies. PLF, on the other hand, is a protein produced by activated T lymphocytes [9] . High levels of this protein were found also in patients with coeliac disease [16] and in multiple sclerosis (unpublished observation) which manifest other autoimmune diseases with T cell involvement. In coeliac patients, it was found that PLF was produced by the lymphocytes infiltrating the gut, the target organ in this disease (unpublished observations). The origin of serum PLF in Type 1 diabetes is as yet unknown. However, it may be suggested that PLF originates from T lymphocytes which infiltrate the diabetic pancreas. Direct involvement of T cell interference in Type 1 diabetes was first observed by Gepts [18] and Botazzo et al. [19] . Both groups described "insulitis" characterised by lymphocyte infiltration in the pancreas of a diabetic child who died soon after the onset of the disease. The infiltrate constituted mainly of T cytotoxic/suppressor ceils, T helper, and B cells. Therefore, the high PLF level may be considered a manifestation of T cell involvement in the disease.
T lymphocytes from peripheral blood of Type 1 diabetes patients can suppress secretion of insulin from cultures of islet beta-cells [20] . Recently, de Berardinis et 72 PLF = placental isoferritin; (-) Placental isoferritin 0-10 U/ml; ( + ) placental isoferritin above 10 U/ml al. [21] showed that CD4 positive activated T cell clones isolated from a Type i diabetes patient of acute onset were specifically cytotoxic to islet Beta-cells.
In addition, Pak et al. [22] recently demonstrated the presence of human cytomegalovirus specific viral genome in the lymphocytes of 15 newly diagnosed Type i diabetes patients, suggesting an association between persistent cytomegalovirus infection and Type i diabetes.
The current study shows for the first time a new marker (PLF) of T cell activation of high incidence in Type 1 diabetic patients and their family members. Among the family members the incidence of positive PLF was highest in healthy siblings. This finding may suggest that these subjects are at the highest risk for developing Type 1 diabetes and may need further evaluation and follow-up.
Of great interest is the observation that PLF was decreased in Type i diabetic patients after short periods (2-28 weeks) of insulin treatment and in those followed up to one year. This may be interpreted as an insulin suppressive effect on activated T lymphocytes producing this protein.
The mechanism of the insulin effect on secretion of PLF is unknown. PLF has been previously shown to exert an immunosuppressive effect [11, 12] and may, thus, participate in alteration of the immune function of Type 1 diabetic patients.
It was previously found that insulin treatment may partially restore the altered function of the immune system in BB rats [23] , in experimental models and in Type 1 diabetes of recent onset [24] , thereby slowing the autoimmune process. Interestingly, a new study demonstrated that intensive insulin therapy during the first two weeks from the onset of Type i diabetes, resulted in an improved islet Beta-cell function during the subsequent year [25] . Inhibition of PLF secretion by insulin may be responsible for part of this restorative effect.
The results of this study may further support the recently projected trial for insulin pre-treatment of family members at high risk. This treatment may result in a decreased PLF level, restoration of immunological functions and a reduced risk of developing diabetes.
